Research programme: amyotrophic lateral sclerosis vaccines - Amorfix

Drug Profile

Research programme: amyotrophic lateral sclerosis vaccines - Amorfix

Latest Information Update: 18 Dec 2014

Price : $50

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Vaccines
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Amyotrophic lateral sclerosis

Most Recent Events

  • 08 Aug 2014 Suspended - Preclinical for Amyotrophic lateral sclerosis in Canada (Parenteral)
  • 13 Aug 2013 Research programme: amyotrophic lateral sclerosis vaccines - Amorfix is available for licensing as of 13 August 2013. http://www.amorfix.com
  • 30 Jun 2013 Amyotrophic lateral sclerosis vaccines no longer licensed to Pan-Provincial Vaccine Enterprise
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top